Showing results (121-130 of 149) with videos related to
Sort By:
Pageof 15
Advances in Therapy|September 22, 2022
Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational StudyJanet Pope, Stephen Hall, Claire Bombardier, et al.Journal of Synchrotron Radiation|July 30, 2024
New opportunities for time-resolved imaging using diffraction-limited storage ringsZisheng Yao, Julia Rogalinski, Eleni Myrto Asimakopoulou, et al.Scientific Reports|February 14, 2019
Analysis of SMALP co-extracted phospholipids shows distinct membrane environments for three classes of bacterial membrane proteinAlvin C K Teo, Sarah C Lee, Naomi L Pollock, et al.The Journal of Rheumatology|January 17, 2015
Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritisArthur Kavanaugh, Philip J Mease, Juan J Gomez-Reino, et al.Methods in Molecular Biology (Clifton, N.J.)|May 19, 2026
Complex Structural Examination of Protein-Lipid Interactions with Neutron Scattering TechniquesNajet Mahmoudi, Hannah Johnston, Sophie E Ayscough, et al.The New England Journal of Medicine|October 19, 2017
Tofacitinib or Adalimumab versus Placebo for Psoriatic ArthritisPhilip Mease, Stephen Hall, Oliver FitzGerald, et al.Annals of the Rheumatic Diseases|June 10, 2015
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)Gerd R Burmester, Andrea Rubbert-Roth, Alain Cantagrel, et al.Annals of the Rheumatic Diseases|August 2, 2013
A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)Gerd R Burmester, Andrea Rubbert-Roth, Alain Cantagrel, et al.Lancet (London, England)|November 20, 2016
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE studyJosef S Smolen, Gerd-Rüdiger Burmester, Bernard Combe, et al.The New England Journal of Medicine|June 19, 2014
Tofacitinib versus methotrexate in rheumatoid arthritisEun Bong Lee, Roy Fleischmann, Stephen Hall, et al.Pageof 15